Local view for "http://purl.org/linkedpolitics/eu/plenary/2004-01-14-Speech-3-126"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20040114.2.3-126"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
The Commission’s Programme for Action entitled ‘accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction; outstanding policy issues and future challenges’ was based on three approaches: improving effectiveness, making medicines more affordable and increasing R[amp]D (Research and Development).
I endorse the rapporteur’s proposal to encourage patent-holder companies to grant licences that allow other companies to manufacture their products at lower cost; using safeguards in international trade agreements that can help governments to expand access to medicines and protect public health.
We need to see more R[amp]D and new medicines and instruments of diagnosis that are easier to use, more effective and more affordable. Similarly, particular emphasis must be given to disseminating routine child and maternal health care, so as to reduce mortality rates. The EU must not remain indifferent to such issues and its financial contribution must increase accordingly.
I voted in favour, as I feel that the problems arising from poverty-linked disease are so serious that only by establishing a broad range of far-reaching policies and strategies will we be able to solve them in all their aspects."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples